Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) +/- antibody induction in simultaneous pancreas kidney (SPK) transplantation: one year results

Go back to Resources

Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) +/- antibody induction in simultaneous pancreas kidney (SPK) transplantation: one year results

Authors:

Location:

Go back to Resources

Synagis® (Palivizumab) Prophylaxis of Respiratory Syncytial Virus (RSV) Infection - Patient Dempgraphics and Preliminary Results from 2000-2001 Synagis® Outcomes Registry

Go back to Resources

Synagis® (Palivizumab) Prophylaxis of Respiratory Syncytial Virus (RSV) Infection - Patient Dempgraphics and Preliminary Results from 2000-2001 Synagis® Outcomes Registry

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Synagisâ (Palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection - patient demographics and preliminary results from the 2000-2001 SynagisÒ Outcomes Registry

Go back to Resources

Synagisâ (Palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection - patient demographics and preliminary results from the 2000-2001 SynagisÒ Outcomes Registry

Authors:

Location:

Go back to Resources

Studies in pediatric liver transplantation (SPLIT): Year 2000 outcomes

Go back to Resources

Studies in pediatric liver transplantation (SPLIT): Year 2000 outcomes

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Severity of RSV LRI hospitalizations in 33 to 35 week and 36 week gestational age infants

Go back to Resources

Severity of RSV LRI hospitalizations in 33 to 35 week and 36 week gestational age infants

Authors:

Location:

Go back to Resources

Safety and Immunogenicity of a Recombinant Hemagglutinin Vaccine for H5 Influenza in Humans

Go back to Resources

Safety and Immunogenicity of a Recombinant Hemagglutinin Vaccine for H5 Influenza in Humans

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

Go back to Resources

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Go back to Resources

Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Risk factors for anemia during erythropoietin therapy among pediatric dialysis patients: a North American Pediatric Cooperative Study (NAPRTCS) Report

Go back to Resources

Risk factors for anemia during erythropoietin therapy among pediatric dialysis patients: a North American Pediatric Cooperative Study (NAPRTCS) Report

Authors:

Location:

Go back to Resources

Risk factors associated with age-related nuclear and cortical cataract - A case-control study in the age-related eye disease study. AREDS Report No. 5

Go back to Resources

Risk factors associated with age-related nuclear and cortical cataract - A case-control study in the age-related eye disease study. AREDS Report No. 5

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 125
  • Page 126
  • Page 127
  • Page 128
  • Current page 129
  • Page 130
  • Page 131
  • Page 132
  • Page 133
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions